Corcept Therapeutics CORT Accrued Marketing and Advertising Expenses
Accrued Marketing and Advertising Expenses at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccruedMarketingCostsCurrent.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's accrued marketing and advertising expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's accrued marketing and advertising expenses?
- Corcept Therapeutics (CORT) reported accrued marketing and advertising expenses of $13.59M in Q1 2026.
- How has Corcept Therapeutics's accrued marketing and advertising expenses changed year-over-year?
- Corcept Therapeutics's accrued marketing and advertising expenses increased by 223.7% year-over-year, from $4.2M to $13.59M.
- What is the long-term trend for Corcept Therapeutics's accrued marketing and advertising expenses?
- Over 5 years (2020 to 2025), Corcept Therapeutics's accrued marketing and advertising expenses has grown at a 74.0% compound annual growth rate (CAGR), from $665K to $10.61M.